Compile Data Set for Download or QSAR
Report error Found 170 Enz. Inhib. hit(s) with all data for entry = 8776
TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419139(N-(4-ethylphenyl)-N- isobutyl-3- methanesulfonoxim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419139(N-(4-ethylphenyl)-N- isobutyl-3- methanesulfonoxim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419139(N-(4-ethylphenyl)-N- isobutyl-3- methanesulfonoxim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419139(N-(4-ethylphenyl)-N- isobutyl-3- methanesulfonoxim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461063(CHEMBL4226803 | US10457637, Compound 8)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461063(CHEMBL4226803 | US10457637, Compound 8)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461065(CHEMBL4225020 | US10457637, Compound 18)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461065(CHEMBL4225020 | US10457637, Compound 18)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419154(N-(4-ethylphenyl)-N- isobutyl-3-methanesulfinyl- 4...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419154(N-(4-ethylphenyl)-N- isobutyl-3-methanesulfinyl- 4...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419155(N-(4-ethylphenyl)-N- isobutyl-3-methanesulfinyl- 4...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419157(N-(4-ethylphenyl)-3- hydroxymethyl-N-isobutyl- 4-(...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461068(CHEMBL4228069 | US10457637, Compound 24)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419162(N-(4-ethylphenyl)-4-((4- fluorotetrahydro-2H-pyran...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419162(N-(4-ethylphenyl)-4-((4- fluorotetrahydro-2H-pyran...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419163(4-((3- oxabicyclo[3.1.0]hexan-6- yl)methoxy)-N-(4-...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419167(4-(((1R,5S,6R)-3- oxabicyclo[3.1.0]hexan-6- yl)met...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419169(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonom...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461074(CHEMBL4227729 | US10457637, Compound 52)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461074(CHEMBL4227729 | US10457637, Compound 52)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461066(CHEMBL4228566 | US10457637, Compound 53)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461066(CHEMBL4228566 | US10457637, Compound 53)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461075(CHEMBL4225072 | US10457637, Compound 55)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461075(CHEMBL4225072 | US10457637, Compound 55)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419189(N-(4-ethylphenyl)-4-(((3- hydroxycyclobutyl)methyl...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419189(N-(4-ethylphenyl)-4-(((3- hydroxycyclobutyl)methyl...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461083(CHEMBL4225889 | US10457637, Compound 62)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461083(CHEMBL4225889 | US10457637, Compound 62)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419192(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419192(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461069(CHEMBL4228522 | US10457637, Compound 66)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461069(CHEMBL4228522 | US10457637, Compound 66)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419214(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419214(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419218(4-((((1R,5S,6S)-3- oxabicyclo[3.1.0]hexan-6- yl)me...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419218(4-((((1R,5S,6S)-3- oxabicyclo[3.1.0]hexan-6- yl)me...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419225(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419225(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419233(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419234(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419242(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419242(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461076(CHEMBL4227214 | US10457637, Compound 124)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461076(CHEMBL4227214 | US10457637, Compound 124)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419252(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419252(N-(4-ethylphenyl)-N- isobutyl-3-(S- methylsulfonim...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419256(N-(2,4-dimethylphenyl)-N- isobutyl-3-(S- methylsul...)
Affinity DataIC50: 100nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetInterleukin-17A(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419256(N-(2,4-dimethylphenyl)-N- isobutyl-3-(S- methylsul...)
Affinity DataIC50: 100nMAssay Description:This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM50461070(CHEMBL4227173 | US10457637, Compound 2)
Affinity DataIC50: 550nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM419144(N-(4-ethylphenyl)-3- hydroxymethyl-N-isobutyl- 4-(...)
Affinity DataIC50: 550nMAssay Description:The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/7/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 170 total ) | Next | Last >>
Jump to: